| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6429230 | LEADIANT BIOSCI INC | Treating chronic uremic patients undergoing periodical dialysis |
Jan, 2021
(3 years ago) | |
| US6335369 | LEADIANT BIOSCI INC | Treating chronic uremic patients undergoing periodical dialysis |
Jan, 2021
(3 years ago) | |
| US6696493 | LEADIANT BIOSCI INC | Treating chronic uremic patients undergoing periodic dialysis |
Jan, 2021
(3 years ago) | |
Carnitor is owned by Leadiant Biosci Inc.
Carnitor contains Levocarnitine.
Carnitor has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Carnitor are:
- US6429230
- US6335369
- US6696493
Carnitor was authorised for market use on 16 December, 1992.
Carnitor is available in injectable;injection dosage forms.
Carnitor can be used as use of levocarnitine in prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.
The generics of Carnitor are possible to be released after 18 January, 2021.
Drugs and Companies using LEVOCARNITINE ingredient
Market Authorisation Date: 16 December, 1992
Treatment: Use of levocarnitine in prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis
Dosage: INJECTABLE;INJECTION
CARNITOR family patents
